ARAZLO

Peak

tazarotene

NDATOPICALLOTION
Approved
Dec 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10

Mechanism of Action

form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of…

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
NCT04071756Phase 2Terminated

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

Started Dec 2019
8 enrolled
Solid TumorHand-Foot Skin Reaction (HFSR)
NCT01119651Phase 1Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Started Jun 2010
59 enrolled
Acne Vulgaris
NCT01115322Phase 1Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Started Apr 2010
38 enrolled
Acne Vulgaris
NCT01114841Phase 1Completed

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers

Started Mar 2010
254 enrolled
Acne Vulgaris

Loss of Exclusivity

LOE Date
May 11, 2038
148 months away
Patent Expiry
May 11, 2038

Patent Records (3)

Patent #ExpiryTypeUse Code
11679116
Jun 6, 2036
Product
11311482
May 11, 2038
U-2368
12128137
May 11, 2038
Product
U-2368